JP2010500293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500293A5 JP2010500293A5 JP2009523120A JP2009523120A JP2010500293A5 JP 2010500293 A5 JP2010500293 A5 JP 2010500293A5 JP 2009523120 A JP2009523120 A JP 2009523120A JP 2009523120 A JP2009523120 A JP 2009523120A JP 2010500293 A5 JP2010500293 A5 JP 2010500293A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- pharmaceutically acceptable
- acceptable salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- 150000003839 salts Chemical class 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 101150109738 Ptger4 gene Proteins 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 159000000000 sodium salts Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000005309 thioalkoxy group Chemical group 0.000 claims 1
- 0 CC(NS(*)(=O)=O)=O Chemical compound CC(NS(*)(=O)=O)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83725206P | 2006-08-11 | 2006-08-11 | |
| US60/837,252 | 2006-08-11 | ||
| PCT/CA2007/001404 WO2008017164A1 (en) | 2006-08-11 | 2007-08-10 | Thiophenecarboxamide derivatives as ep4 receptor ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010500293A JP2010500293A (ja) | 2010-01-07 |
| JP2010500293A5 true JP2010500293A5 (enExample) | 2010-09-16 |
| JP5259592B2 JP5259592B2 (ja) | 2013-08-07 |
Family
ID=39032586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009523120A Expired - Fee Related JP5259592B2 (ja) | 2006-08-11 | 2007-08-10 | Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8969394B2 (enExample) |
| EP (1) | EP2054401B1 (enExample) |
| JP (1) | JP5259592B2 (enExample) |
| CN (1) | CN101541778B (enExample) |
| AU (1) | AU2007283404B2 (enExample) |
| CA (1) | CA2660133C (enExample) |
| ES (1) | ES2421453T3 (enExample) |
| WO (1) | WO2008017164A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009005076A1 (ja) * | 2007-07-03 | 2009-01-08 | Astellas Pharma Inc. | アミド化合物 |
| CA2694347A1 (en) * | 2007-08-09 | 2009-02-12 | Merck Sharp & Dohme Corp. | Process for making thiophene carboxamide derivative |
| BRPI0912778B1 (pt) * | 2008-05-14 | 2019-04-30 | Astellas Pharma Inc. | Composto de amida, composição farmacêutica compreendedo dito composto e uso do mesmo para o tratamento de insuficiência renal crônica ou nefropatia diabética |
| WO2010019796A1 (en) * | 2008-08-14 | 2010-02-18 | Chemietek, Llc | Heterocyclic amide derivatives as ep4 receptor antagonists |
| CN102655859A (zh) | 2009-10-14 | 2012-09-05 | 格穆斯药业股份有限公司 | 病毒感染的组合疗法治疗 |
| CN107693518A (zh) * | 2010-02-22 | 2018-02-16 | 株式会社ＡｓｋＡｔ | Ep‑4受体拮抗剂在治疗il‑23介导疾病中的用途 |
| CN103097358B (zh) | 2010-09-21 | 2015-04-08 | 卫材R&D管理有限公司 | 药物组合物 |
| CA2820109C (en) | 2010-12-10 | 2018-01-09 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| ES2938840T3 (es) | 2013-03-19 | 2023-04-17 | Askat Inc | Uso de antagonistas del receptor EP4 en el tratamiento de enfermedad del cartílago |
| US10391086B2 (en) | 2013-03-19 | 2019-08-27 | Askat Inc. | Use of EP4 receptor antagonists in the treatment of cartilage disease |
| NO3009426T3 (enExample) | 2013-06-12 | 2018-09-29 | ||
| KR20220147691A (ko) | 2013-08-09 | 2022-11-03 | 알데릭스, 인코포레이티드 | 인산염 수송을 억제하기 위한 화합물 및 방법 |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| CN106572993B (zh) * | 2014-05-23 | 2019-07-16 | 卫材R&D管理有限公司 | Ep4拮抗剂在制备治疗癌症的药物中的应用 |
| CN106458859B (zh) * | 2014-06-06 | 2019-08-30 | 阿勒根公司 | 作为治疗性化合物的新型ep4激动剂 |
| CN105037186A (zh) * | 2015-06-17 | 2015-11-11 | 苏州敬业医药化工有限公司 | 一种氨甲苯酸的制备方法 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| WO2018162562A1 (en) | 2017-03-10 | 2018-09-13 | Bayer Pharma Aktiengesellschaft | Use of an ep4 antagonist for the treatment of inflammatory pain |
| AR111807A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2 |
| ES2887041T3 (es) | 2017-05-18 | 2021-12-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de PGE2 |
| EP3625223B1 (en) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| DK3625224T3 (da) | 2017-05-18 | 2021-11-08 | Idorsia Pharmaceuticals Ltd | N-substituerede indolderivater |
| ES2893452T3 (es) | 2017-05-18 | 2022-02-09 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de PGE2 |
| WO2019038156A1 (en) | 2017-08-22 | 2019-02-28 | Bayer Pharma Aktiengesellschaft | USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS |
| US10202415B1 (en) | 2017-10-19 | 2019-02-12 | King Saud University | Method of synthesizing of 3-oxolupenal nanoparticles |
| EP3972599B1 (en) | 2019-05-21 | 2025-10-22 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
| CN112552200B (zh) * | 2019-09-10 | 2024-03-12 | 烟台药物研究所 | 一种光学纯4-(1-氨基)乙基苯甲酸酯及其盐的制备方法 |
| IL300471A (en) * | 2020-08-18 | 2023-04-01 | Hutchison Medipharma Ltd | Pyrimidinone compounds and their uses |
| US20230390303A1 (en) | 2020-11-13 | 2023-12-07 | Ono Pharmaceutical Co., Ltd. | Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| EP0752421B1 (en) | 1995-07-07 | 2005-10-12 | AstraZeneca AB | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists |
| KR20030072614A (ko) * | 2001-01-31 | 2003-09-15 | 화이자 프로덕츠 인크. | Ｐｄｅ４ 이소자임 억제제로 유용한 티아졸릴-,옥사졸릴-, 피롤릴- 및 이미다졸릴-산 아미드 유도체 |
| WO2004099127A1 (en) * | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Novel compounds as kinase inhibitors |
| KR100747401B1 (ko) * | 2003-09-03 | 2007-08-08 | 화이자 인코포레이티드 | 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물 |
| GB0324269D0 (en) * | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| CN1946391A (zh) * | 2004-04-20 | 2007-04-11 | 辉瑞产品公司 | 包含α－2－δ配体的组合 |
| WO2005105733A1 (en) * | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Ortho substituted aryl or heteroaryl amide compounds |
| WO2005105732A1 (en) * | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Substituted methyl aryl or heteroaryl amide compounds |
| WO2005116010A1 (en) | 2004-05-26 | 2005-12-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
-
2007
- 2007-08-10 JP JP2009523120A patent/JP5259592B2/ja not_active Expired - Fee Related
- 2007-08-10 WO PCT/CA2007/001404 patent/WO2008017164A1/en not_active Ceased
- 2007-08-10 AU AU2007283404A patent/AU2007283404B2/en not_active Ceased
- 2007-08-10 CA CA2660133A patent/CA2660133C/en not_active Expired - Fee Related
- 2007-08-10 ES ES07815782T patent/ES2421453T3/es active Active
- 2007-08-10 CN CN200780037574.4A patent/CN101541778B/zh not_active Expired - Fee Related
- 2007-08-10 US US12/309,941 patent/US8969394B2/en active Active
- 2007-08-10 EP EP07815782.3A patent/EP2054401B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010500293A5 (enExample) | ||
| JP2011527331A5 (enExample) | ||
| JP2008539267A5 (enExample) | ||
| JP2019034943A5 (enExample) | ||
| JP2013056886A5 (enExample) | ||
| JP2006143751A5 (enExample) | ||
| JP2015505296A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| JP2014524442A5 (enExample) | ||
| JP2009507909A5 (enExample) | ||
| JP2010522710A5 (enExample) | ||
| JP2009524676A5 (enExample) | ||
| EA022527B1 (ru) | 2-ЗАМЕЩЕННЫЕ-8-АЛКИЛ-7-ОКСО-7,8-ДИГИДРОПИРИДО[2,3-d]ПИРИМИДИН-6-КАРБОНИТРИЛЫ И ИХ ПРИМЕНЕНИЕ | |
| JP2008513496A5 (enExample) | ||
| JP2010523476A5 (enExample) | ||
| JP2013512277A5 (enExample) | ||
| JP2012502927A5 (enExample) | ||
| RU2010119458A (ru) | 1,3,5-тризамещенное производное триазола | |
| JP2013511556A5 (enExample) | ||
| JP2011523952A5 (enExample) | ||
| JP2007522142A5 (enExample) | ||
| JP2013514980A5 (enExample) | ||
| JP2013521301A5 (enExample) | ||
| JP2018513832A5 (enExample) | ||
| JP2018521121A5 (enExample) |